Our brains are the key to who we are.
At Re: Cognition Health we are changing the future for those with memory loss and other symptoms of cognitive impairment, through providing education, clinical excellence and access to the most advanced treatments available, worldwide.
This is an exciting time for potential new treatments for Alzheimer’s disease and other causes of mild cognitive impairment (MCI) and dementia. The Re: Cognition Health clinical trials team led by Dr Emer MacSweeney and Dr Stephen Pearson are running a number of international clinical studies providing early access to new and more effective medications in the final phase of development. These medications include those designed to halt or very significantly slow down progression of Alzheimer’s disease and those developed to boost memory and improve other cognitive symptoms. The purpose of a final phase study is to verify, on a large number of people living in different countries the successful results already gained in earlier phase studies. If successful, the pharmaceutical company applies for an international license for the new medication to be available on the market.